CD24, A Review of its Role in Tumor Diagnosis, Progression and Therapy

被引:31
作者
Ni, Yang-Hong [1 ,2 ,3 ,4 ]
Zhao, Xia [4 ]
Wang, Wei [1 ,2 ,3 ]
机构
[1] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Chengdu 610041, Sichuan, Peoples R China
[2] Sichuan Univ, West China Hosp, Canc Ctr, Chengdu 610041, Sichuan, Peoples R China
[3] Collaborat Innovat Ctr Biotherapy, Chengdu 610041, Sichuan, Peoples R China
[4] Sichuan Univ, Dev & Related Dis Women & Children Key Lab Sichua, Dept Gynecol & Obstet,Minist Educ, West China Hosp 2,Key Lab Birth Defects & Related, Chengdu 610041, Sichuan, Peoples R China
关键词
CD24; cancer; mAb; immunotherapy; lymphocytes; granulocytes; HEAT-STABLE ANTIGEN; INDEPENDENT PROGNOSTIC MARKER; STEM-CELL MARKERS; INVASIVE DUCTAL CARCINOMA; OVARIAN-CANCER CELLS; HUMAN B-CELLS; BREAST-CANCER; HEPATOCELLULAR-CARCINOMA; DOWN-REGULATION; COLORECTAL-CANCER;
D O I
10.2174/1566523220666200623170738
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
CD24, is a mucin-like GPI-anchored molecules. By immunohistochemistry, it is widely detected in many solid tumors, such as breast cancers, genital system cancers, digestive system cancers, neural system cancers and so on. The functional roles of CD24 are either fulfilled by combination with ligands or participate in signal transduction, which mediate the initiation and progression of neoplasms. However, the character of CD24 remains to be intriguing because there are still opposite voices about the impact of CD24 on tumors. In preclinical studies, CD24 target therapies, including monoclonal antibodies, target silencing by RNA interference and immunotherapy, have shown us brighten futures on the anti-tumor application. Nevertheless, evidences based on clinical studies are urgently needed. Here, with expectancy to spark new ideas, we summarize the relevant studies about CD24 from a tumor perspective.
引用
收藏
页码:109 / 126
页数:18
相关论文
共 234 条
[1]  
ABRAMSON CS, 1981, J IMMUNOL, V126, P83
[2]   GON4L Drives Cancer Growth through a YY1-Androgen Receptor-CD24 Axis [J].
Agarwal, Neeraj ;
Dancik, Garrett M. ;
Goodspeed, Andrew ;
Costello, James C. ;
Owens, Charles ;
Duex, Jason E. ;
Theodorescu, Dan .
CANCER RESEARCH, 2016, 76 (17) :5175-5185
[3]   CD24 expression is an independent prognostic marker in cholangiocarcinoma [J].
Agrawal, Shefali ;
Kuvshinoff, Boris W. ;
Khoury, Thaer ;
Yu, Jihnhee ;
Javle, Milind M. ;
LeVea, Charles ;
Groth, Jeff ;
Coignet, Lionel J. ;
Gibbs, John F. .
JOURNAL OF GASTROINTESTINAL SURGERY, 2007, 11 (04) :445-451
[4]   CD24 shows early upregulation and nuclear expression but is not a prognostic marker in colorectal cancer [J].
Ahmed, M. A. H. ;
Al-Attar, A. ;
Kim, J. ;
Watson, N. F. S. ;
Scholefield, J. H. ;
Durrant, L. G. ;
Ilyas, M. .
JOURNAL OF CLINICAL PATHOLOGY, 2009, 62 (12) :1117-1122
[5]   CD24 is Upregulated in Inflammatory Bowel Disease and Stimulates Cell Motility and Colony Formation [J].
Ahmed, Mohamed A. H. ;
Jackson, Darryl ;
Seth, Rashmi ;
Robins, Adrian ;
Lobo, Dileep N. ;
Tomlinson, Ian P. M. ;
Ilyas, Mohammad .
INFLAMMATORY BOWEL DISEASES, 2010, 16 (05) :795-803
[6]   CD24 mediates rolling of breast carcinoma cells on P-selectin [J].
Aigner, S ;
Ramos, CL ;
Hafezi-Moghadam, A ;
Lawrence, MB ;
Friederichs, J ;
Altevogt, P ;
Ley, K .
FASEB JOURNAL, 1998, 12 (12) :1241-1251
[7]   CD24, a mucin-type glycoprotein, is a ligand for P-selectin on human tumor cells [J].
Aigner, S ;
Sthoeger, ZM ;
Fogel, M ;
Weber, E ;
Zarn, J ;
Ruppert, M ;
Zeller, Y ;
Vestweber, D ;
Stahel, R ;
Sammar, M ;
Altevogt, P .
BLOOD, 1997, 89 (09) :3385-3395
[8]  
[Anonymous], 2012, BMC GASTROENTEROL, DOI DOI 10.1186/1471-230X-12-96
[9]   Prognostic Significance of CD24 in Clear Cell Renal Cell Carcinoma [J].
Arik, Deniz ;
Can, Cavit ;
Dundar, Emine ;
Kabukcuoglu, Sare ;
Pasaoglu, Ozgul .
PATHOLOGY & ONCOLOGY RESEARCH, 2017, 23 (02) :409-416
[10]   CD24 expression has a prognostic impact in breast carcinoma [J].
Athanassiadou, Pauline ;
Grapsa, Dimitra ;
Gonidi, Maria ;
Athanassiadou, Anna-Maria ;
Tsipis, Angelos ;
Patsouris, Efstratios .
PATHOLOGY RESEARCH AND PRACTICE, 2009, 205 (08) :524-533